Keyphrases
High Dose
100%
Marrow
100%
Non-Hodgkin Lymphoma
100%
Dose Intensification
100%
Peripheral Blood
50%
Granulocyte Colony-stimulating Factor (G-CSF)
50%
Lymphoma Patients
50%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
50%
Hemoglobin Level
25%
Human Hemoglobin
25%
Neutrophils
25%
Tumor Cells
25%
Minimal Residual Disease
25%
Complete Remission
25%
Platelets
25%
Therapeutic Potential
25%
Overall Survival
25%
Pretransplant
25%
Blood Tumors
25%
Erythropoietin
25%
Therapeutic Monoclonal Antibody
25%
Grafting from
25%
5-year Survival
25%
Autograft
25%
Anti-CD20 Antibody
25%
VP16
25%
Autografting
25%
Melphalan
25%
Poor Risk
25%
Myeloablative
25%
Carmustine
25%
Hematopoietic Recovery
25%
Cytosine Arabinoside
25%
Tumor Contamination
25%
Normal Hematopoiesis
25%
Anti-CD20 Treatment
25%
Relapse Incidence
25%
Therapeutic Era
25%
BEAM Regimen
25%
Nursing and Health Professions
Neoplasm
100%
Drug Megadose
100%
Nonhodgkin Lymphoma
100%
Patient with Non-Hodgkins Lymphoma
100%
Autologous Stem Cell Transplantation
100%
Drug Dose Intensification
100%
Remission
50%
Infusion
50%
Hemoglobin Blood Level
50%
Erythropoietin
50%
Overall Survival
50%
Autograft
50%
Granulocyte Colony Stimulating Factor
50%
Minimal Residual Disease
50%
Disease Free Survival
50%
Melphalan
50%
Rituximab
50%
Cytarabine
50%
Carmustine
50%
Granulocyte Macrophage Colony Stimulating Factor
50%
Medicine and Dentistry
Drug Megadose
100%
Cytokine
100%
Patient with Non-Hodgkins Lymphoma
100%
Drug Dose Intensification
100%
Non-Hodgkin Lymphoma
66%
Autologous Stem Cell Transplantation
66%
Infusion
33%
Neoplasm
33%
Hematopoiesis
33%
Minimal Residual Disease
33%
Tumor Cell
33%
Granulocyte Colony Stimulating Factor
33%
Platelet
33%
Granulocyte Macrophage Colony Stimulating Factor
33%
Overall Survival
33%
Disease Free Survival
33%
Autograft
33%
Rituximab
33%
Erythropoietin
33%
CD20
33%
Melphalan
33%
Cytarabine
33%
Carmustine
33%
Neutrophil
33%
Immunology and Microbiology
Cytokine
100%
Drug Megadose
100%
Drug Dose Intensification
100%
Autologous Stem Cell Transplantation
66%
Neutrophil
33%
CD20
33%
Hematopoiesis
33%
Tumor Cell
33%
Granulocyte Colony-Stimulating Factor
33%
Granulocyte Macrophage Colony-Stimulating Factor
33%
Platelet
33%
Hemoglobin Blood Level
33%
Overall Survival
33%
Rituximab
33%
Erythropoietin
33%
Disease Free Survival
33%
Autograft
33%
Pharmacology, Toxicology and Pharmaceutical Science
Nonhodgkin Lymphoma
100%
Cytokine
100%
Neoplasm
50%
Remission
25%
Minimal Residual Disease
25%
Overall Survival
25%
Disease Free Survival
25%
Rituximab
25%
Erythropoietin
25%
Granulocyte Colony Stimulating Factor
25%
Granulocyte Macrophage Colony Stimulating Factor
25%
Carmustine
25%
Melphalan
25%
Cytarabine
25%